Nuvectis Pharma (NASDAQ:NVCT) Stock Price Down 7.7% – Should You Sell?

Nuvectis Pharma, Inc. (NASDAQ:NVCT) shares fell 7.7% during trading on Friday . The stock traded as low as $25.00 and last traded at $25.7120. Approximately 90,266 shares traded hands during mid-day trading, a decline of 6% from the average daily volume of 96,170 shares. The stock had previously closed at $27.87.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on NVCT shares. Wall Street Zen raised Nuvectis Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. HC Wainwright raised their price target on Nuvectis Pharma from $13.00 to $39.00 and gave the stock a “buy” rating in a research report on Monday, June 22nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvectis Pharma in a research note on Friday, June 5th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Nuvectis Pharma has an average rating of “Hold” and a consensus target price of $39.00.

Nuvectis Pharma Stock Performance

The firm has a market cap of $721.35 million, a PE ratio of -20.76 and a beta of -0.07. The company’s 50-day simple moving average is $11.46 and its two-hundred day simple moving average is $9.41.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. On average, analysts expect that Nuvectis Pharma, Inc. will post -1.01 EPS for the current year.

Institutional Trading of Nuvectis Pharma

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in Nuvectis Pharma by 4.8% during the 3rd quarter. Vanguard Group Inc. now owns 698,708 shares of the company’s stock valued at $4,206,000 after purchasing an additional 31,903 shares during the period. Iridian Asset Management LLC CT lifted its holdings in Nuvectis Pharma by 44.5% in the 4th quarter. Iridian Asset Management LLC CT now owns 586,320 shares of the company’s stock worth $4,427,000 after buying an additional 180,699 shares during the period. Baldwin Wealth Partners LLC MA lifted its holdings in Nuvectis Pharma by 11.2% in the 4th quarter. Baldwin Wealth Partners LLC MA now owns 389,625 shares of the company’s stock worth $2,942,000 after buying an additional 39,164 shares during the period. Occam Crest Management LP grew its position in shares of Nuvectis Pharma by 31.0% in the 4th quarter. Occam Crest Management LP now owns 380,000 shares of the company’s stock worth $2,869,000 after buying an additional 90,000 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Nuvectis Pharma by 11.8% in the 4th quarter. Geode Capital Management LLC now owns 364,024 shares of the company’s stock worth $2,749,000 after buying an additional 38,291 shares during the last quarter. 96.77% of the stock is owned by institutional investors.

Nuvectis Pharma Company Profile

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.